Research programme: therapeutic cancer vaccines - NCI/Intensity Therapeutics

Drug Profile

Research programme: therapeutic cancer vaccines - NCI/Intensity Therapeutics

Alternative Names: INT 223-8

Latest Information Update: 21 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Intensity Therapeutics
  • Developer Intensity Therapeutics; National Cancer Institute (USA)
  • Class Cancer vaccines; Platinum complexes
  • Mechanism of Action DNA cross linking agents; DNA synthesis inhibitors; Immunostimulants; Natural killer cell receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 15 Jun 2017 Intensity Therapeutics has patents pending for its cancer vaccines in Australia
  • 15 Jun 2017 Intensity Therapeutics receives patent allowance for its DfuseRxSM technology platform in USA
  • 02 Jun 2014 Therapeutic cancer vaccines are available for licensing as of 02 Jun 2014.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top